<DOC>
	<DOCNO>NCT00083213</DOCNO>
	<brief_summary>RATIONALE : VEGF Trap may stop growth solid tumor non-Hodgkin 's lymphoma stopping blood flow tumor . PURPOSE : This phase I trial study side effect best dose intravenous VEGF Trap treat patient relapsed refractory advance solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Intravenous VEGF Trap Treating Patients With Relapsed Refractory Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability intravenous VEGF Trap patient relapse refractory advance solid tumor non-Hodgkin 's lymphoma . Secondary - Determine maximum tolerate intravenous dose drug patient . - Determine pharmacokinetics drug patient . - Determine ability drug bind circulate vascular endothelial growth factor patient . - Determine , preliminarily , ability drug alter tumor blood flow tumor vascular permeability patient . - Determine whether antibody drug develop patient . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive VEGF Trap IV 1 hour day 1 15 total 2 dos . Cohorts 3-6 patient receive escalate dos VEGF Trap maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional 6 patient treat dose level . In absence dose-limiting toxicity , patient stable disease partial complete remission may continue receive VEGF Trap separate extension protocol . Patients follow week 1 , 3 , 7 3 month . PROJECTED ACCRUAL : A maximum 25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : NonHodgkin 's lymphoma Primary metastatic solid tumor locate , radiography , least one follow site : Liver Soft tissue Pelvis Other site suitable delay contrastenhanced MRI ( e.g. , peripheral lung field ) Relapsed refractory ( include unresectable ) disease Patients solid tumor must fail curative chemotherapeutic regimen Patients nonHodgkin 's lymphoma must refractory least 2 standard chemotherapeutic regimen rituximab Not amenable available conventional therapy AND standard therapy exist Measurable disease No prior concurrent CNS metastasis ( brain leptomeningeal ) No primary intracranial tumor MRI CT scan No histologically confirm squamous cell carcinoma lung PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC ≥ 3,500/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 No severe uncontrolled hematologic condition Hepatic Bilirubin ≤1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN PT PTT normal INR normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine ≤ ULN Urine protein/creatinine ratio ≤ 1 No severe uncontrolled renal condition Cardiovascular No clinically significant acute electrocardiographic abnormality LVEF normal echocardiogram MUGA within past 12 month prior exposure anthracyclines No untreated uncontrolled hypertension No blood pressure &gt; 150/100 mm Hg ( despite treatment ) No isolated systolic hypertension ( i.e. , systolic blood pressure &gt; 180 mm Hg least 2 determination [ separate day ] within past 3 month ) No New York Heart Association class II IV heart disease No active coronary artery disease require acute medical management No angina require acute medical management No congestive heart failure require acute medical management No ventricular arrhythmia require acute medical management No stroke transient ischemic event within past 6 month No prior concurrent peripheral vascular disease No angiographically ultrasonographically document arterial venous occlusive event No symptomatic claudication No symptomatic orthostatic hypotension No severe uncontrolled cardiovascular condition Pulmonary No severe uncontrolled pulmonary condition No pulmonary embolism within past 6 month Immunologic HIV negative No severe uncontrolled immunologic condition No active current infection require antibiotic No prior hypersensitivity reaction recombinant protein , include VEGF Trap Other No severe uncontrolled gastrointestinal musculoskeletal condition No psychiatric condition adverse social circumstance would preclude study participation No condition would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublebarrier contraception 3 month study treatment PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior participation VEGF Trap , interleukin1 Trap , interleukin4/13 Trap clinical trial At least 3 week since prior immunotherapy recover No concurrent epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy recover Endocrine therapy No concurrent adrenal corticosteroid except lowdose replacement therapy No concurrent systemic hormonal contraceptive agent Radiotherapy At least 3 week since prior radiotherapy recover Surgery At least 3 week since prior major laparoscopic surgery recover More 6 month since prior surgical procedure correction prophylaxis peripheral vascular insufficiency cerebral ischemic event Other More 30 day since prior investigational drug No concurrent anticoagulant antiplatelet drug ( e.g. , warfarin , heparin , aspirin ) lowdose ( 1 mg ) warfarin maintain patency venous access device No concurrent nonsteroidal antiinflammatory drug , include cyclooxygenase2 ( COX2 ) inhibitors No concurrent anticancer investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent penile cancer</keyword>
	<keyword>stage IV penile cancer</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent vulvar cancer</keyword>
	<keyword>stage IVB vulvar cancer</keyword>
	<keyword>distal urethral cancer</keyword>
	<keyword>proximal urethral cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>